Acuta Capital Partners LLC Buys Shares of 386,500 COMPASS Pathways plc (NASDAQ:CMPS)

Acuta Capital Partners LLC purchased a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 386,500 shares of the company’s stock, valued at approximately $2,435,000. COMPASS Pathways accounts for 2.0% of Acuta Capital Partners LLC’s holdings, making the stock its 18th largest position. Acuta Capital Partners LLC owned about 0.56% of COMPASS Pathways as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. acquired a new position in COMPASS Pathways during the 2nd quarter worth about $81,000. Green Alpha Advisors LLC acquired a new stake in shares of COMPASS Pathways during the third quarter worth about $99,000. Kennedy Capital Management LLC purchased a new position in shares of COMPASS Pathways in the first quarter valued at approximately $139,000. Tidal Investments LLC grew its holdings in shares of COMPASS Pathways by 43.6% in the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after purchasing an additional 5,795 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in COMPASS Pathways during the 1st quarter worth approximately $201,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the transaction, the insider now directly owns 6,905,774 shares of the company’s stock, valued at approximately $41,779,932.70. This trade represents a 27.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.25% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CMPS has been the subject of several recent research reports. Maxim Group decreased their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada dropped their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group lowered their target price on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. HC Wainwright cut their price target on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $30.67.

COMPASS Pathways Price Performance

Shares of CMPS opened at $4.56 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 1-year low of $4.05 and a 1-year high of $12.75. The stock has a market cap of $312.00 million, a PE ratio of -2.07 and a beta of 2.29. The firm has a fifty day moving average price of $5.74 and a 200 day moving average price of $6.61.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same period in the previous year, the company earned ($0.67) earnings per share. As a group, sell-side analysts anticipate that COMPASS Pathways plc will post -2.33 EPS for the current year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.